SCHEMBL6017209

SCHEMBL6017209

Nc1ccc2c(=O)n(-c3ccc(C(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)[nH]c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.54
TP53 P04637 4/20 0.43
MAPT P10636 1/20 0.41
RXFP1 Q9HBX9 3/20 0.40
KMT2A Q03164 3/20 0.39
GAA P10253 3/20 0.39
HTR3A P46098 3/20 0.39
LMNA P02545 3/20 0.38
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 2/20 0.38
GLA P06280 1/20 0.38
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
USP2 O75604 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4412669 0.88 P2RY12 (0.70) P2RY12TP53MAPTRXFP1KMT2A
SCHEMBL13635285 0.88 P2RY12 (0.63) P2RY12TP53MAPTRXFP1KMT2A
SCHEMBL13638520 0.87 P2RY12 (0.47) P2RY12TP53MAPTRXFP1KMT2A
SCHEMBL9920071 0.87 P2RY12 (0.53) P2RY12TP53MAPTRXFP1KMT2A
SCHEMBL13634952 0.87 P2RY12 (0.54) P2RY12TP53MAPTRXFP1KMT2A
SCHEMBL13635180 0.85 P2RY12 (0.56) P2RY12TP53MAPTRXFP1KMT2A
SCHEMBL13638527 0.85 P2RY12 (0.45) P2RY12TP53MAPTRXFP1KMT2A
SCHEMBL13635177 0.84 P2RY12 (0.57) P2RY12TP53MAPTRXFP1KMT2A
SCHEMBL13635179 0.83 P2RY12 (0.54) P2RY12TP53MAPTRXFP1KMT2A
SCHEMBL4415315 0.83 P2RY12 (0.52) P2RY12TP53MAPTRXFP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1668002-B1 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS PORTOLA PHARM INC (US) 2009-11-11 EP disclosed
EP-1668002-A4 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS PORTOLA PHARM INC (US) 2006-12-20 EP disclosed
US-7109332-B2 2,4-dioxo-3-quinazolinylaryl sulfonylureas PORTOLA PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
EP-1668002-A2 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS Portola Pharmaceuticals, Inc. (US) 2006-06-14 EP disclosed
US-20050107357-A1 2,4-dioxo-3-quinazolinylaryl sulfonylureas PORTOLA PHARMACEUTICALS, INC. (US) 2005-05-19 US disclosed
WO-2005032488-A2 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS PORTOLA PHARMACEUTICALS, INC. (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107357-A1 2,4-dioxo-3-quinazolinylaryl sulfonylureas PFKP, DPP3, P2RY13 P2RY12 21/4885TP53 3744/4885MAPT 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.